This title discusses all aspects of non-infectious and non-cancer- so called NINC - vaccines. Hypertension, diabetes and allergy vaccine development are referred to as well as the use of adjuvants and nanotechnology in vaccine development. The way of novel vaccines from bench to preclinical to clinical studies and launch to the market under EMEA (European Medicines Agency) and FDA (Food and Drug Administration) guidelines are described in-depth. The book is therefore of interest for researchers and clinicians engaged in vaccine development and molecular vaccine application.